Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

IONS

株式のランク #2553
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
株価
$45.20
時価総額
$7.51B
変化(1日)
1.85%
変化(1年)
-38.55%
国
US
取引 Ionis Pharmaceuticals, Inc. (IONS)

カテゴリー

Healthcare
Ionis Pharmaceuticals, Inc.(IONS)の発行済株式数
June 2026 時点の発行済株式数 165.42M
Ionis Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 165.42M です。December 2023 の終わりには、同社は 143.00M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Ionis Pharmaceuticals, Inc.(IONS)の発行済株式数の履歴(2000 ~ 2026)
各年末時点の発行済株式数
年 発行済株式数 変化
2026 (TTM) 165.42M 10.64%
2024 149.51M 4.56%
2023 143.00M 0.81%
2022 141.85M 0.59%
2021 141.02M 1.01%
2020 139.61M -0.28%
2019 140.00M 5.80%
2018 132.32M 6.70%
2017 124.02M 2.66%
2016 120.80M 1.26%
2015 119.29M 1.36%
2014 117.69M 6.51%
2013 110.50M 9.87%
2012 100.58M 0.92%
2011 99.66M 0.52%
2010 99.14M 1.05%
2009 98.11M 3.75%
2008 94.57M 12.93%
2007 83.74M 12.69%
2006 74.31M 18.18%
2005 62.88M 11.01%
2004 56.64M 2.13%
2003 55.46M 1.80%
2002 54.48M 23.51%
2001 44.11M 19.14%
2000 37.02M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数 差 国
253.90M 53.49%
US
396.00M 139.39%
US
478.91M 189.51%
AU
- -
CH
62.19M -62.41%
NL